June, 2025
June 2025
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Martin Zapata Laguado: KN564 maintain benefit on OS in ccRCC
Jun 2, 2025, 06:19

Martin Zapata Laguado: KN564 maintain benefit on OS in ccRCC

Martin Zapata Laguado, Clinical Oncologist at the National Cancer Institute E.S.E., shared on X:

“ASCO 2025 update data on KN564 maintain benefit on OS, all patients in the trial benefit from Pembrolizumab adjuvant, however we lack more biomarkers perhaps a measure in KIM1 would be outstanding.”